Back to Journals » Drug, Healthcare and Patient Safety » Volume 7

Cardiovascular effects of hormone therapy for prostate cancer

Authors Lester J, Mason M

Received 2 March 2015

Accepted for publication 30 April 2015

Published 23 July 2015 Volume 2015:7 Pages 129—138

DOI https://doi.org/10.2147/DHPS.S50549

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Professor Shu-Feng Zhou


Jason F Lester,1 Malcolm D Mason1,2

1Velindre Hospital, Whitchurch, 2School of Medicine, Cardiff University, Heath Park, Cardiff, UK

Abstract:
Androgen deprivation therapy (ADT) has been the mainstay of treatment for advanced prostate cancer for decades, and has been shown to control disease and improve symptoms. In addition, for men with high-risk localized or locally advanced prostate cancer, short-course ADT in combination with radiotherapy improves survival. There is evidence that ADT increases cardiovascular risk, particularly in men with preexisting cardiovascular disease. This increased risk may apply even with short-course ADT. In an individual patient, the benefits of ADT should be balanced against the risk, and patients who require ADT should have risk factors for cardiovascular disease optimized. There is some evidence to suggest that more contemporary methods of delivering ADT may reduce cardiovascular risk.

Keywords: androgen deprivation therapy, testosterone, cardiovascular risk, hypercoagulability, prostate cancer patients, dihydrotestosterone, androgen receptor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]